Perhaps the new CFO can offer some other creative financing alternatives to the management team as well as show them "cause and effect" details of standard financing means. i.e. R/S to raise price, lower share count, and create poor shareholder support - however, releasing revenue generating product, or new institutional investment, or PR on favorable clinical approvals could all be considered as "cause and effect" for management decision-making, and thus stimulate shareholder support.